Regentys is an early-stage Florida corporation that manufactures medical devices for gastrointestinal applications. The company's ECMH product is a hydrogel composed of extracellular matrix derived from porcine tissue, which has been proven safe and effective in esophageal repair, hernia grafts, vaginal slings, and burn and wound dressings. Regentys' novel application of this technology will treat Ulcerative Colitis, a debilitating disease that renders the colon dysfunctional. The company's therapy will be positioned to compete in a multi-billion-dollar market dominated by biologic and drug therapies that can have significant side effects.